NCT02172911 - A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 6, 2014

Primary Completion Date

September 7, 2017

Study Completion Date

September 7, 2017

Conditions

Cervical Cancer

Interventions

BIOLOGICAL

INO-3112

1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.

DEVICE

CELLECTRA™-5P

CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.

Trial Locations (3)

10032

Columbia University Medical Center, New York

48109

University of Michigan, Ann Arbor

60637

University of Chicago Medical Center, Chicago